What Opportunities for Orphan Drugs Exist in Specialty Pharmacy?

In this video, Gordon Vanscoy, PharmD, MBA, explains how policy changes and science have allowed orphan drugs to enter the specialty pharmacy market and create hope for patients.


"Orphan drugs presented a tremendous opportunity and it was really all created because of policy changes. The Orphan Drug Act, The Pediatric Voucher Act, really stimulated the opportunity for manufactures to bring more products to market and that stimulation obviously advanced the science, and policy and science together created a significant increase in the number of orphan products that came to market. So, the opportunity that we had was is being able to see this happen and see that it occurred, and orphan products end up being a significant part of specialty products. So, these babies, these adults, these individuals that we’re treating are individuals with not only rare but devastating disease states and it’s so rewarding to be able to bring something to them where they’ve never had hope before."       

Most Popular

Related Articles

Biologic therapy used to treat severe psoriasis found to improve coronary artery plaque burden.
There are currently no FDA-approved therapies for the prevention or treatment of acute graft-versus-host disease.
Top news of the week from Specialty Pharmacy Times.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.